Novo Stock Is Down More Than 70% From Its Peak. Value Trap or Generational Buying Opportunity?
Key PointsNovo Nordisk rose dramatically because investors were excited after it launched the first GLP-1 weight-loss drug.
We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.